Anemia in chronic heart failure: modern concepts of pathogenesis and treatment

Olga N. Kryuchkova , Anna M. Vinnikova , Karina V. Sivak , Andrey S. Safonov , Elena V. Chayko , Ekaterina N. Morgovka , Danila D. Morgovka , Kirill O. Golovin

For citation:

Abstract

Chronic heart failure (CHF) is one of the most urgent medical and social problems in the 21st century. Its prevalence is constantly increasing, acquiring the scale of a modern epidemic. This problem is interdisciplinary in nature and requires an integrated approach to its solution. One of the concomitant diseases in CHF is anemia, which exacerbates hemodynamic disorders and has a negative impact on the prognosis for patients. Understanding the mechanisms of anemia syndrome development in patients with CHF is of key importance for developing an optimal treatment strategy. This review examines the pathogenetic aspects of anemia formation in patients with CHF and possible methods of its drug correction. Google Scholar, PubMed, and eLibrary databases were used to search for scientific literature. The terms "chronic heart failure", "anemia", "iron carboxymaltose" and "cardiorenal anemia syndrome" were chosen as keywords. The review included full-text scientific articles and literature reviews directly related to the topic of anemia in patients with CHF. Materials that did not meet the established research criteria were excluded from the analysis.

Keywords: chronic heart failure, anemia, iron carboxymaltose, cardiorenal anemia syndrome.

References

1. Groenewegen A, Rutten FH, Mosterd A et al. Epidemiology of heart failure. Eur J Heart Fail 2020;22(8):1342-56. DOI: 10.1002/ ejhf.1858

2. Галявич А.С., Терещенко С.Н., Ускач Т.М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162. DOI: 10.15829/1560-4071-2024-6162

Galyavich A.S., Tereshchenko S.N., Uskach T.M. et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. DOI: 10.15829/1560-4071-2024-6162 (in Russian).

3. Соломахина Н.И., Находнова Е.С., Ершов В.И. Анемия при хронической сердечной недостаточности: роль гепсидина как универсального регулятора метаболизма железа. Журнал Сердечная Недостаточность. 2014;85(4):254-60.

Solomakhina N.I., Nakhodnova E.S., Ershov V.I. Anemia in chronic heart failure: the role of hepcidin as a universal regulator of iron metabolism. J Heart Failure. 2014;85(4):254-60 (in Russian).

4. Раджеш Р., Гаскина А.А., Виллевальде С.В., Кобалава Ж.Д. Клинические ассоциации анемии у пациентов с хронической сердечной недостаточностью. Клиническая фармакология и терапия. 2018;27(4):12-6.

Rajesh R., Gaskina A.A., Villevalde S.V., Kobalava Z.D. Clinical associations of anemia in patients with chronic heart failure. Clinical Pharmacology and Therapy. 2018;27(4):12-6 (in Russian).

5. Ebner N, Jankowska EA, Ponikowski P et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int J Cardiol 2016;(205):6-12. DOI: 10.1016/j.ijcard.2015.11.178

6. Nemeth E, Preza GC, Jung CL et al. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-functionstudy. Blood 2006;107(1):328-33. DOI: 10.1182/blood-2005-05-2049

7. Муркамилов И.Т., Калиев Р.Р., Сарыбаев А.Ш. и др. Хронический ренокардиальный континуум при гломерулонефрите. Кардиология. 2016;56(9):55-9. DOI: 10.18565/cardio.2016.9.55-59

Murkamilov I.T., Kaliev R.R., Sarybaev A.Sh. et al. Chronic renocardial continuum in glomerulonephritis. Cardiology. 2016;56(9):55-9. DOI: 10.18565/cardio.2016.9.55-59 (in Russian).

8. Anand IS, Ferrari R, Kalra GS et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;(80):299-305.

9. Opasich C, Cazzola M, Scelsi L et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;(26):2232-7.

10. Эттингер О.А., Зеновко И.К., Гендлин Г.Е. Анемия при хронической болезни почек: роль препаратов железа. Рекомендации по ведению больных. Лечебное дело. 2014;(4):38-46.

Ettinger O.A., Zenovko I.K., Gendlin G.E. Anemia in chronic kidney disease: the role of iron supplements. Recommendations for patient management. General Medicine. 2014;(4):38-46 (in Russian).

11. Ватутин Н.Т., Тарадин Г.Г., Канишева И.В. и др. Анемия и железодефицит у больных с хронической сердечной недостаточностью. Кардиология. 2019;59(4S):4-20. DOI: 10.18087/cardio.2638

Vatutin N.T., Taradin G.G., Kanishcheva I.V. et al. Anaemia and iron deficiency in chronic heart failure patients. Cardiology. 2019;59(4S):4-20. DOI: 10.18087/cardio.2638 (in Russian).

12. Kassem KM, Vaid S, Peng H et al. Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system? Can J Physiol Pharmacol 2019;97(7):589-99. DOI: 10.1139/cjpp-2018-0570

13. Ishani A, Weinhandl E, Zhao Z et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005;45(3):391-9. DOI: 10.1016/j.jacc.2004.10.038

14. Ахматов В.Ю., Печенкина М.В., Носов С.В. Особенности лабораторных показателей у пациентов с хронической болезнью почек, находящихся на программном гемодиализе. Медицинский совет. 2016;1(31):6-8.

Akhmatov V.Yu., Pechenkina M.V., Nosov S.V. Features of laboratory parameters in patients with chronic kidney disease undergoing program hemodialysis. Medical Council. 2016;1(31):6-8 (in Russian).

15. Graham FJ, Pellicori P, Kalra PR et al. Intravenous iron in patients with heart failure and iron deficiency: an updated meta‐analysis. Eur J Heart Failure 2023;25(4):528-37. DOI: 10.1002/ejhf.2810

16. Anker SD, Comin Colet J, Filippatos G et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;(361):2436-48. DOI: 10.1056/NEJMoa0908355

17. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36(11):657-68. DOI: 10.1093/eurheartj/ehu385

For citation:Kryuchkova O.N., Vinnikova A.M., Sivak K.V., Safonov A.S., Chayko E.V., Morgovka E.N., Morgovka D.D., Golovin K.O. Anemia in chronic heart failure: modern concepts of pathogenesis and treatment. Clinical review for general practice. 2026; 7 (5): 14–17 (In Russ.). DOI: 10.47407/kr2026.7.5.00832

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice